Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 44 articles:
HTML format
Text format



Single Articles


    March 2017
  1. BASULI D, Tesfay L, Deng Z, Paul B, et al
    Iron addiction: a novel therapeutic target in ovarian cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  2. COMISSO E, Scarola M, Rosso M, Piazza S, et al
    OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  3. GUPTA R, Yang Q, Dogra SK, Wajapeyee N, et al
    Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    February 2017
  4. LAU TS, Chan LK, Wong EC, Hui CW, et al
    A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFalpha-TGFalpha-EGFR.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    January 2017
  5. ZHAO L, Ji G, Le X, Luo Z, et al
    An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.
    Oncogene. 2017 Jan 23. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    December 2016
  6. MODI DA, Tagare RD, Karthikeyan S, Russo A, et al
    PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Oncogene. 2016 Dec 19. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    November 2016
  7. WILSON C, Qiu L, Hong Y, Karnik T, et al
    The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  8. DIMITROVA N, Nagaraj AB, Razi A, Singh S, et al
    InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer.
    Oncogene. 2016 Nov 7. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    October 2016
  9. MATSUURA K, Huang NJ, Cocce K, Zhang L, et al
    Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  10. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  11. WITT AE, Lee CW, Lee TI, Azzam DJ, et al
    Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    September 2016
  12. FANG D, Chen H, Zhu JY, Wang W, et al
    Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2016 Sep 12. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  13. CHAN DW, Hui WW, Wang JJ, Yung MM, et al
    DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-beta/SMAD4 signaling.
    Oncogene. 2016 Sep 5. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  14. WANG Y, Justilien V, Brennan KI, Jamieson L, et al
    PKCiota regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.
    Oncogene. 2016 Jun 20. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  15. SAINI U, Naidu S, ElNaggar AC, Bid HK, et al
    Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.
    Oncogene. 2016 Jun 13. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    April 2016
  16. OZES AR, Miller DF, Ozes ON, Fang F, et al
    NF-kappaB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.
    Oncogene. 2016 Apr 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    March 2016
  17. ZHANG L, Ma T, Brozick J, Babalola K, et al
    Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
    Oncogene. 2016 Mar 14. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    February 2016
  18. SEVIOUR EG, Sehgal V, Lu Y, Luo Z, et al
    Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.
    Oncogene. 2016;35:801.
    PubMed     Text format    


    January 2016
  19. PARK CS, Kim TK, Kim HG, Kim YJ, et al
    Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis.
    Oncogene. 2016 Jan 25. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  20. YAGI H, Asanoma K, Ohgami T, Ichinoe A, et al
    GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer.
    Oncogene. 2016 Jan 25. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  21. GEORGE SH, Milea A, Sowamber R, Chehade R, et al
    Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis.
    Oncogene. 2016;35:59-68.
    PubMed     Text format     Abstract available


    December 2015
  22. DUCKWORTH C, Zhang L, Carroll SL, Ethier SP, et al
    Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.
    Oncogene. 2015 Dec 14. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    November 2015
  23. SHIGETA S, Toyoshima M, Kitatani K, Ishibashi M, et al
    Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer.
    Oncogene. 2015 Nov 9. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    October 2015
  24. PANGON L, Ng I, Giry-Laterriere M, Currey N, et al
    JRK is a positive regulator of beta-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer.
    Oncogene. 2015 Oct 12. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    September 2015
  25. CHEN J, Bai M, Ning C, Xie B, et al
    Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1alpha/cyclin D1 pathway.
    Oncogene. 2015 Sep 14. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  26. KITATANI K, Usui T, Sriraman SK, Toyoshima M, et al
    Ceramide limits phosphatidylinositol-3-kinase C2beta-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.
    Oncogene. 2015 Sep 14. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    August 2015
  27. NAGARAJA AS, Dorniak PL, Sadaoui NC, Kang Y, et al
    Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.
    Oncogene. 2015 Aug 10. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  28. PRUDNIKOVA TY, Villamar-Cruz O, Rawat SJ, Cai KQ, et al
    Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.
    Oncogene. 2015 Aug 10. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    July 2015
  29. TIMSAH Z, Ahmed Z, Ivan C, Berrout J, et al
    Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.
    Oncogene. 2015 Jul 27. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  30. SHINDERMAN-MAMAN E, Cohen K, Weingarten C, Nabriski D, et al
    The thyroid hormone-alphavbeta3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation.
    Oncogene. 2015 Jul 13. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    June 2015
  31. YAN L, Zhou J, Gao Y, Ghazal S, et al
    Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation.
    Oncogene. 2015;34:3076-84.
    PubMed     Text format     Abstract available


  32. GOLMARD L, Delnatte C, Lauge A, Moncoutier V, et al
    Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.
    Oncogene. 2015 Jun 1. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    April 2015
  33. CARVALHO S, Lindzen M, Lauriola M, Shirazi N, et al
    An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.
    Oncogene. 2015 Apr 27. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  34. HE Y, Wu AC, Harrington BS, Davies CM, et al
    Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
    Oncogene. 2015 Apr 20. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  35. TUTHILL MH, Montinaro A, Zinngrebe J, Prieske K, et al
    TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
    Oncogene. 2015;34:2138-44.
    PubMed     Text format     Abstract available


  36. ZHU X, Shen H, Yin X, Long L, et al
    miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.
    Oncogene. 2015 Apr 13. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    March 2015
  37. MITRA AK, Chiang CY, Tiwari P, Tomar S, et al
    Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis.
    Oncogene. 2015 Mar 23. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  38. HE C, Lv X, Hua G, Lele SM, et al
    YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression.
    Oncogene. 2015 Mar 23. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  39. ADAMS MN, Harrington BS, He Y, Davies CM, et al
    EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.
    Oncogene. 2015;34:1375-83.
    PubMed     Text format     Abstract available


    February 2015
  40. LIN YG, Shen J, Yoo E, Liu R, et al
    Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis.
    Oncogene. 2015 Feb 16. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  41. SEVIOUR EG, Sehgal V, Lu Y, Luo Z, et al
    Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.
    Oncogene. 2015 Feb 2. doi: 10.1038/onc.2014.
    PubMed     Text format     Abstract available


    August 2014
  42. LEVANON K, Sapoznik S, Bahar-Shany K, Brand H, et al
    FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis.
    Oncogene. 2014;33:4424-32.
    PubMed     Text format     Abstract available


  43. PAUL BT, Blanchard Z, Ridgway M, ElShamy WM, et al
    BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
    Oncogene. 2014 Aug 18. doi: 10.1038/onc.2014.
    PubMed     Text format     Abstract available


    January 2014
  44. LABIDI-GALY SI, Clauss A, Ng V, Duraisamy S, et al
    Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.
    Oncogene. 2014 Jan 27. doi: 10.1038/onc.2013.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: